Literature DB >> 21151153

Cabazitaxel: a new drug for metastatic prostate cancer.

Marijo Bilusic1, William L Dahut.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21151153      PMCID: PMC3592929          DOI: 10.1038/aja.2010.161

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  9 in total

1.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

2.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Authors:  Howard I Scher; Tomasz M Beer; Celestia S Higano; Aseem Anand; Mary-Ellen Taplin; Eleni Efstathiou; Dana Rathkopf; Julia Shelkey; Evan Y Yu; Joshi Alumkal; David Hung; Mohammad Hirmand; Lynn Seely; Michael J Morris; Daniel C Danila; John Humm; Steve Larson; Martin Fleisher; Charles L Sawyers
Journal:  Lancet       Date:  2010-04-14       Impact factor: 79.321

3.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

4.  Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors.

Authors:  C Sessa; C Cuvier; S Caldiera; J Bauer; S Van Den Bosch; C Monnerat; D Semiond; D Pérard; A Lebecq; M Besenval; M Marty
Journal:  Ann Oncol       Date:  2002-07       Impact factor: 32.976

5.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.

Authors:  X Pivot; P Koralewski; J L Hidalgo; A Chan; A Gonçalves; G Schwartsmann; S Assadourian; J P Lotz
Journal:  Ann Oncol       Date:  2008-04-23       Impact factor: 32.976

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

8.  Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.

Authors:  Tracy A Brooks; Hans Minderman; Kieran L O'Loughlin; Paula Pera; Iwao Ojima; Maria R Baer; Ralph J Bernacki; Tracy Brooks
Journal:  Mol Cancer Ther       Date:  2003-11       Impact factor: 6.261

Review 9.  Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.

Authors:  F K Engels; A Sparreboom; R A A Mathot; J Verweij
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.